The remarkable journey of Calliditas Therapeutics and its groundbreaking drug, Tarpeyo, sheds light on the company’s innovative strategies and relentless pursuit of excellence that led to the successful approval of Tarpeyo by the U.S. Food and Drug Administration (FDA) for the treatment of a specific kidney disease. Our guest in this episode, Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, reveals how their pioneering approach to drug development has set a new benchmark in the pharmaceutical industry.

We explore how Calliditas Therapeutics' groundbreaking work in securing FDA approval not only marks a significant milestone for the company but also inspires a new wave of innovation in the treatment of kidney diseases. Discover the power of pioneering drug development and the bright future it heralds for patients worldwide.

This episode also features insights from Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, highlighting the importance of the Drugs to Watch 2024 report and the potential of Tarpeyo – one of 13 drugs to watch included in the report – to significantly improve patient outcomes.

Discover a story of resilience, innovation, and success behind Tarpeyo's journey to the American market, and the broader implications for the pharmaceutical industry's approach to drug development and regulatory approval.